Search research articles
Contact Us
Filters
Showing results (131-140 of 208) with videos related to
Page
of 21
Sort By:
Nature Communications
|
November 26, 2014
ERG induces taxane resistance in castration-resistant prostate cancer
Giuseppe Galletti, Alexandre Matov, Himisha Beltran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 11, 2018
Expression of AR-V7 and ARv<sup>567es</sup> in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY
Scott T Tagawa, Emmanuel S Antonarakis, Ada Gjyrezi, et al.
The Prostate
|
September 1, 2020
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting
Andrea K Miyahira, Kenneth J Pienta, John W Babich, et al.
Molecular Oncology
|
March 1, 2022
The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy
Johannes C van der Mijn, Kenneth W Eng, Pooja Chandra, et al.
European Urology
|
January 7, 2024
Safety Analyses of the Phase 3 VISION Trial of [<sup>177</sup>Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
Kim N Chi, Andrew J Armstrong, Bernd J Krause, et al.
European Urology Open Science
|
April 27, 2023
Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Arlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 23, 2024
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3
Petros Grivas, Damien Pouessel, Chandler H Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2018
Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline
Justin E Bekelman, R Bryan Rumble, Ronald C Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2021
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
Scott T Tagawa, Arjun V Balar, Daniel P Petrylak, et al.
Nature Medicine
|
February 9, 2016
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Himisha Beltran, Davide Prandi, Juan Miguel Mosquera, et al.
Page
of 21
Search research articles
Search
Showing results (131-140 of 208) with videos related to
Sort By:
Page
of 21
Nature Communications
|
November 26, 2014
ERG induces taxane resistance in castration-resistant prostate cancer
Giuseppe Galletti, Alexandre Matov, Himisha Beltran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 11, 2018
Expression of AR-V7 and ARv<sup>567es</sup> in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY
Scott T Tagawa, Emmanuel S Antonarakis, Ada Gjyrezi, et al.
The Prostate
|
September 1, 2020
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting
Andrea K Miyahira, Kenneth J Pienta, John W Babich, et al.
Molecular Oncology
|
March 1, 2022
The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy
Johannes C van der Mijn, Kenneth W Eng, Pooja Chandra, et al.
European Urology
|
January 7, 2024
Safety Analyses of the Phase 3 VISION Trial of [<sup>177</sup>Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
Kim N Chi, Andrew J Armstrong, Bernd J Krause, et al.
European Urology Open Science
|
April 27, 2023
Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Arlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 23, 2024
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3
Petros Grivas, Damien Pouessel, Chandler H Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2018
Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline
Justin E Bekelman, R Bryan Rumble, Ronald C Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2021
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
Scott T Tagawa, Arjun V Balar, Daniel P Petrylak, et al.
Nature Medicine
|
February 9, 2016
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Himisha Beltran, Davide Prandi, Juan Miguel Mosquera, et al.
Page
of 21